130 related articles for article (PubMed ID: 21192466)
1. [Increased risk of cancer using insulin and insulin analogues?].
Schäffler A
MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
[No Abstract] [Full Text] [Related]
2. Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine.
Nagel JM; Mansmann U; Wegscheider K; Röhmel J
Diabetologia; 2010 Jan; 53(1):206-8. PubMed ID: 19774358
[No Abstract] [Full Text] [Related]
3. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.
Simon D
Diabetologia; 2010 Jan; 53(1):204-5. PubMed ID: 19859691
[No Abstract] [Full Text] [Related]
4. [Long acting insulin analogues: results of clinical studies with insulin glargine].
Fritsche A
Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S101-5; discussion S124-6. PubMed ID: 18686217
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine and incidence of cancer--an ongoing debate.
Hermanns N; Kulzer B
J Diabetes Sci Technol; 2010 Mar; 4(2):497-8. PubMed ID: 20307414
[No Abstract] [Full Text] [Related]
6. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
7. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
8. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
[No Abstract] [Full Text] [Related]
9. Diabetic retinopathy and insulin glargine.
Chantelau E
Diabetologia; 2009 Oct; 52(10):2233; author reply 2236-9. PubMed ID: 19680626
[No Abstract] [Full Text] [Related]
10. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
Butler PC
Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
[No Abstract] [Full Text] [Related]
11. [Diabetes, insulin, insulin analogues, and cancer].
Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
[TBL] [Abstract][Full Text] [Related]
12. Risk of cancer in patients receiving insulin glargine.
Dawson LK; Hamilton LA
Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
[TBL] [Abstract][Full Text] [Related]
13. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes.
Schmid C; Krayenbühl P; Wiesli P
Diabetologia; 2009 Dec; 52(12):2668-9. PubMed ID: 19774359
[No Abstract] [Full Text] [Related]
14. Insulin glargine (Lantus) and cancer risk.
Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
[No Abstract] [Full Text] [Related]
15. Putting insulin glargine and malignancies into perspective.
Ehninger G; Schmidt AH
Oncologist; 2009 Dec; 14(12):1169-74. PubMed ID: 20007644
[No Abstract] [Full Text] [Related]
16. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
17. A possible link between insulin glargine and malignancy: the facts.
Mollentze WF
Cardiovasc J Afr; 2009; 20(4):216-8; discussion 218-9. PubMed ID: 19701528
[No Abstract] [Full Text] [Related]
18. Insulin glargine and the risk of cancer.
Ahmed FA
Cardiovasc J Afr; 2010; 21(1):49. PubMed ID: 20224847
[No Abstract] [Full Text] [Related]
19. Mitogenic action of insulin: friend, foe or 'frenemy'?
Draznin B
Diabetologia; 2010 Feb; 53(2):229-33. PubMed ID: 19851749
[TBL] [Abstract][Full Text] [Related]
20. Initiating basal insulin therapy in patients with type 2 diabetes mellitus.
Stoneking K
Am J Health Syst Pharm; 2005 Mar; 62(5):510-8. PubMed ID: 15745915
[No Abstract] [Full Text] [Related]
[Next] [New Search]
